Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$4.34M | -$6.81M | -$28.7M |
| Net income | -$7.79M | -$8.88M | -$28.8M |
| EPS (diluted) | -$1.46 | -$1.28 | -$0.98 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$3.01M | -$7.28M | -$14.2M |
| Capital expenditures | — | — | $466K |
| Free cash flow | — | — | -$14.7M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $39.0K | $5.53M | $270K |
| Total assets | $798K | $5.54M | $6.84M |
| Total liabilities | $24.8M | $4.73M | $11.9M |
| Shareholders' equity | -$24.0M | -$3.27M | -$6.10M |
| Retained earnings | -$29.5M | -$38.4M | -$67.2M |
| Shares (wtd avg diluted) | 5.34M | 6.95M | 29.3M |
Every figure is extracted from OS Therapies Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.